Correlates of one-year survival inpatients with cardiogenic shock complicating acute myocardial infarction
Angiographic findings from the SHOCK trial
Timothy A. Sanborn, MD*,*,
Lynn A. Sleeper, ScD ,
John G. Webb, MD ,
John K. French, MBChB, PhD ,
Geoffrey Bergman, MB, BS||,
Manish Parikh, MD||,
S. Chiu Wong, MD||,
Jean Boland, MD¶,
Matthias Pfisterer, MD**,
James N. Slater, MD ,
Samin Sharma, MD ,
Judith S. Hochman, MD SHOCK Investigators
* Evanston Northwestern Healthcare, Evanston, Illinois, USA
New England Research Institutes, Inc., Watertown, Massachusetts, USA
St. Paul's Hospital, Vancouver, British Columbia, Canada
Green Lane Hospital, Auckland, New Zealand
|| New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA
¶ CHR Citadelle, Liège, Belgium
** University Hospital, Basel, Switzerland
 St. Luke's-Roosevelt Hospital Center and Columbia University, New York, New York, USA
 Mount Sinai Medical Center, New York, New York, USA
 New York University School of Medicine, New York, New York, USA

View larger version (18K):
[in a new window]
|
Figure 1 One-year survival estimates of "SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK" (SHOCK) trial patients by left ventricular (LV) ejection fraction. Survival rates increase with increasing ejection fraction (p = 0.001), and this relationship is independent of treatment assignment (interaction p = 0.778). For each level of ejection fraction, survival is better for emergency revascularization (ERV) patients. Data frequency for ERV and initial medical stabilization (IMS) patients is shown by fringe on top and bottom of the plot, respectively. Three patients identified as ineligible after randomization due to severe mitral regurgitation or LV free rupture were excluded.
|
|
|